Shiva Sharma, MD
Psychiatry · Albuquerque, NMNPI 1619243193
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $108,464 of the $139,679 with a category attached, or 77.7%. Teva Pharmaceuticals USA, Inc. accounts for 71.6% of it on its own, with 10 other manufacturers making up the rest. 2025 is the largest year on record at $130,637, more than ten times the $46 reported in 2023. Among psychiatry clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 175 payments — averaging $798.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$100K
- Otsuka America Pharmaceutical, Inc.$17K
- Axsome Therapeutics, Inc.$13K
- AbbVie$8K
- Janssen Scientific Affairs, LLC$258
- Alkermes, Inc.$145
- plus $196 from 5 others
What the payments were for
- Speaking & faculty fees$108,46478%
- Travel & lodging$28,24020%
- Food & beverage$2,7642%
- Education$2110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 113 | $99,976 |
| Otsuka America Pharmaceutical, Inc. | 26 | $17,214 |
| Axsome Therapeutics, Inc. | 16 | $13,476 |
| AbbVie | 8 | $8,413 |
| Janssen Scientific Affairs, LLC | 4 | $258 |
| Alkermes, Inc. | 2 | $145 |
| E.r. Squibb & Sons, L.L.C. | 1 | $68 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $53 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $44 |
| Neurocrine Biosciences, Inc. | 1 | $16 |
| Johnson & Johnson | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UZEDY$81,993
- ABILIFY MAINTENA$16,666
- ABILIFY ASIMTUFII$16,666
- Austedo XR$16,164
- Auvelity$13,155
- VRAYLAR$8,266
- ARISTADA$417
- INVEGA SUSTENNA$139
- LYBALVI$104
How this compares
$139,679 in reported general payments places this provider in the 95th percentile of 174 psychiatry providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 21 | $171,100 |
| Invega SustennaPaliperidone Palmitate | 32 | $111,115 |
| Abilify AsimtufiiAripiprazole | 17 | $91,805 |
| VraylarCariprazine Hcl | 26 | $35,829 |
| CaplytaLumateperone Tosylate | 12 | $19,618 |
| Lurasidone Hcl | 19 | $1,919 |
| Trazodone Hcl | 84 | $1,390 |
| Aripiprazole | 16 | $1,090 |
| Prazosin Hcl | 25 | $958 |
| Haloperidol Decanoate | 22 | $609 |
| Topiramate | 35 | $458 |
| Olanzapine | 17 | $300 |
| Propranolol Hcl | 11 | $223 |
| Fluoxetine Hcl | 12 | $205 |
| Sertraline Hcl | 26 | $159 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $16 | $171,10021 claims |
| Johnson & JohnsonInvega Sustenna | $15 | $111,11532 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Asimtufii | $17,214 | $91,80517 claims |
| AbbVieVraylar | $8,413 | $35,82926 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $53 | $19,61812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 174 psychiatry providers in New Mexico.
Other psychiatry in Albuquerque
- Patricio EscalonaAlbuquerque$487K
- Mauricio TohenAlbuquerque$160K
- Javier VeraAlbuquerque$8K
- Nancy MartinAlbuquerque$6K
- Reuben SutterAlbuquerque$5K
- Swala AbramsAlbuquerque$3K
- David EarlAlbuquerque$3K
- Ronald RomanikAlbuquerque$2K
- Anthony HolzgangAlbuquerque$2K
- Mahvish KhanAlbuquerque$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.